Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants

Rhea-AI Summary

Zealand Pharma has announced an increase in share capital due to the exercise of employee warrants. This resulted in the issuance of 3,874 new shares at an exercise price of DKK 100.80 each, yielding total proceeds of DKK 390,500. The share capital will rise to nominal DKK 46,530,384. These new shares will confer rights to dividends and one vote at general meetings. The amendment to the Articles of Association associated with this capital increase has been registered with the Danish Business Authority.

Positive

• Increased share capital by DKK 3,874 through issuance of 3,874 new shares.
• Proceeds from the capital increase amounting to DKK 390,500.
• New shares provide voting rights and dividend eligibility.

Negative

• None.

Company announcement – No. 35 / 2022

Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants

Copenhagen, DK and Boston, MA, August 18, 2022 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, has increased its share capital by a nominal amount of DKK 3,874 divided into 3,874 new shares with a nominal value of DKK 1 each. The increase is a consequence of the exercise of warrants granted under one of Zealand Pharma's employee warrant programs.

Employee warrant programs are part of Zealand Pharma’s incentive scheme, and each warrant gives the owner the right to subscribe for one new Zealand Pharma share at a pre specified price, the exercise price, in specific predefined time periods before expiration. For a more detailed description of Zealand Pharma’s warrant programs, see the company’s Articles of Association, which are available on the website: www.zealandpharma.com.

The exercise price was DKK 100.80 per share for 3,874 of the new shares. The total proceeds to Zealand from the capital increase amount to DKK 390,500.

The new shares give rights to dividend and other rights from the time of the warrant holder's exercise notice. Each new share carries one vote at Zealand Pharma’s general meetings. Zealand Pharma has only one class of shares.

The new shares will be listed on Nasdaq Copenhagen after registration of the capital increase with the Danish Business Authority. Following registration of the new shares, the share capital of Zealand Pharma will be nominal DKK 46,530,384 divided into 46,530,384 shares with a nominal value of DKK 1 each.

The amendments to Zealand Pharma’s Articles of Association entailed by the share capital increase have been set out below. A full copy of the amended Articles of Association can be found at https://www.zealandpharma.com/ and registered today with the Danish Business Authority.

# # #

About Zealand Pharma A/S

Zealand Pharma A/S (Nasdaq: ZEAL) ("Zealand") is a biotechnology company focused on the discovery and development of peptide-based medicines. More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market and three candidates are in late-stage development. In addition, license collaborations with Boehringer Ingelheim and AstraZeneca create opportunities for more patients to potentially benefit from Zealand-invented peptide investigational agents currently in development.
Zealand was founded in 1998 and is headquartered in Copenhagen, Denmark, with a presence in the U.S. that includes Boston. For more information about Zealand’s business and activities, please visit www.zealandpharma.com.

Forward-Looking Statement

The above information contains forward-looking statements that provide Zealand Pharma’s expectations or forecasts of future events, including forward-looking statements about the termination of the Company’s ADR program. Such forward-looking statements are subject to risks, uncertainties and inaccurate assumptions, which may cause actual results to differ materially from expectations set forth herein and may cause any or all of such forward-looking statements to be incorrect. If any or all of such forward-looking statements prove to be incorrect, our actual results could differ materially and adversely from those anticipated or implied by such statements. All such forward-looking statements speak only as of the date of this release and are based on information available to Zealand Pharma as of the date of this release. Except as required by law, the Company assumes no obligation to update these forward-looking statements publicly.

Contact:

Anna Krassowska, PhD Vice President, Investor Relations & Corporate Communications Zealand Pharma Email: ank@zealandpharma.com David Rosen (U.S. Media) Argot Partners Email: media@zealandpharma.com

FAQ

What is the impact of the employee warrant exercise on ZEAL's share capital?

The exercise of employee warrants led to an increase in ZEAL's share capital by DKK 3,874, with the issuance of 3,874 new shares.

How much did Zealand Pharma raise from the capital increase?

Zealand Pharma raised a total of DKK 390,500 from the exercise of employee warrants.

What is the new share capital of Zealand Pharma after the increase?

After the increase, Zealand Pharma's share capital will be nominal DKK 46,530,384.

What rights do the new shares issued by Zealand Pharma confer?

The new shares confer rights to dividends and one vote at Zealand Pharma’s general meetings.

When will the new shares be listed on Nasdaq Copenhagen?

The new shares will be listed on Nasdaq Copenhagen after registration with the Danish Business Authority.